Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Sendai, Japan.
Metrics to compare | 4889 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4889PeersSector | |
|---|---|---|---|---|
P/E Ratio | 611.8x | 10.5x | −0.6x | |
PEG Ratio | 5.35 | 0.09 | 0.00 | |
Price/Book | 13.3x | 2.1x | 2.6x | |
Price / LTM Sales | 239.1x | 2.4x | 3.4x | |
Upside (Analyst Target) | - | 6.7% | 41.5% | |
Fair Value Upside | Unlock | 7.3% | 5.5% | Unlock |